School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Achieve Life Sciences Inc ACHV

Healthcare · Biotechnology

$7.41last close 2026-10-09 · market cap $762.51M · delayed data

Trailing returns

1M-1.72%
3M+15.78%
6M+123.19%
1Y+125.91%
5Y-11.68%

Basis: Adjusted daily closes.

What it does

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Open ACHV in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies